Clinical trial · Interventional
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
NCT01143974CI-TRIAL-00009718completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Malignant Neoplasm | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pemetrexed plus cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PC Regimen
- interventionNames
- Drug: pemetrexed plus cisplatin
Primary outcomes (1)
- measure
- PFS (progression free survival)
- timeFrame
- 2 Years
Secondary outcomes (2)
- measure
- Safety
- timeFrame
- 2 years
- description
- Assessing for Hematology and Non-hematology toxicities, including all SAEs.
- measure
- Response Rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * 18-70 years old * Resistant to enthracycle and taxanes * Has measurable disease Exclusion Criteria: * Has more than 3 previous chemotherapy regimens
References
Publications (0)
Data not yet available
No reference posted for this study.